See feature article below: (NASDAQ: VRML)
Broad Street Alerts recent profiles and track record, 433% in verifiable potential gains for our members on the last 2 small cap alerts alone!
May 11th, 2016- (NASDAQ: STEM) opened $2.92/share hit a high of $3.90/share within a few hours our member potential gains- 33%
May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit 3.26/share within one week for gains of 400% for our members.
Report for: Vermillion, Inc. (NASDAQ: VRML)
Vermillion, Inc. is involved with diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. The company’s shares are up marginally today on average trading volume.
AUSTIN, Texas, May 16, 2016 /PRNewswire/ Vermillion, Inc. (VRML), a bio-analytical solutions company today announced positive top line results from a study entitled, “Clinical Performance Comparison of Two IVDMIAs for Pre-Surgical Assessment of Ovarian Cancer Risk”, presented at the annual meeting of American Congress of Obstetricians and Gynecologists (ACOG), taking place May 14th thru May 17th in Washington DC. Overa™ is Vermillion’s FDA-cleared second-generation version of the OVA1 blood test, used for pre-surgical assessment of ovarian cancer risk in women undergoing surgery for an ovarian (adnexal) mass. ROMA™ (Risk of Ovarian Malignancy Algorithm) is the only other ovarian cancer triage test that has been cleared by FDA.
Overa and ROMA tests were performed on serum from 993 prospectively-enrolled patients who underwent adnexal surgery, the largest head-to-head clinical comparison of two FDA-cleared ovarian cancer triage tests conducted to date. The Overa and ROMA biomarkers were run on the Roche cobas® platform, and high- or low-risk results were determined using the Overa cutoff of 5 and Roche’s ROMA Fact Sheet cutoffs for pre-menopausal or post-menopausal women.
Dr. Lee Shulman, who was first author of the study and serves as Chief of the Division of Obstetrics and Gynecology-Clinical Genetics at Northwestern University in Chicago, IL, stated, “We were especially interested in comparing false negative rates head-to-head with different triage tests in the same patients, since reliable referral of ovarian cancer to specialists is crucial to optimal care and outcomes. Both Overa and ROMA detected more cancers than CA125, which missed almost 30% of all malignancies and almost 40% of early stage cancers. But overall, ROMA missed 51 of the 245 malignancies in this study, including 20 of 84 early-stage ovarian cancers. By comparison, Overa missed 22 malignancies overall and 8 early-stage malignancies – 60% fewer than ROMA.”
Vermillion’s Chief Medical Officer, Dr. Judith Wolf, added, “FDA-cleared tests offer tremendous potential to improve the effectiveness of pre-surgical ovarian cancer risk assessment for women facing surgery for an ovarian mass. The single most important performance measure is false negative rate. Failure to detect a malignancy may result in surgery and treatment by non-specialists, which has been shown to significantly reduce the rate of survival. We are excited by these preliminary results and look forward to publication in a peer-reviewed journal in the near future.”
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women conquer serious diseases. The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Source – Company Press Release
DISCLAIMER
Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
Please Note: We do NOT accept free trading or restricted securities as payment for our services.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.
Stock market
Hot small cap stocks
small cap stock picks
Biotech stocks
FDA approval stocks
FDA calendar
Trade stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news
